Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433765 · ClinicalTrials.gov registry record
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
A clinical trial of Multiple Sclerosis, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- 728
- Enrollment target
- 1
- Study location
NCT06433765 is a study of Multiple Sclerosis that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 728 participants, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (25% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06433765, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- 728 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
North Carolina
- BRIUMVI® Pregnancy Registry Virtual Research Coordination Center - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2035-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433765
The ClinicalTrials.gov registry entry for NCT06433765 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 728 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (25% higher). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT06433765 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06433765 about?
NCT06433765 is a clinical study titled "A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)". The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
What is the current status of trial NCT06433765?
This trial is currently recruiting. The enrollment target is 728 participants. The study started on 2024-06-01. Estimated completion is 2035-03-31.
What conditions does trial NCT06433765 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06433765?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT06433765?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433765 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.